Safety and efficacy of a phase 1 clinical gene therapy trial in patients with advanced heart failure using a rationally designed cardiotropic AAV vector targeting protein phosphatase inhibitor-1
Asklepios BioPharmaceutical, Inc.,, Research Triangle Park (United States of America)
1
presentation
0
follower
6
more
presentations
in this session
Renin-angiotensin-aldosterone system inhibitor discontinuation and its impact on one-year mortality in heart failure patients with acute kidney injury: a propensity matched analysis
Deformation Imaging by Strain in Chronic heart failure Over gliflozins: an Echocardiographic Register on Sodium-GLucose coTransporter-2 inhibitors (DISCOVER SGLT2i)
Age-stratified and sex-stratified effect of angiotensin receptor-neprilysin inhibitor in heart failure with reduced ejection fraction-data from PARADE-HF: nationwide medication adherence study